{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-017192","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.968035+00:00","generated_at":"2026-06-23T23:58:19.543588+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eliem Therapeutics Q2 net loss $14.6M; discontinues ETX-810 Phase 2a after failure","bullets":["Net loss of $14.6M for Q2 2022 vs $8.7M in Q2 2021; cash, equivalents, securities $134.7M.","ETX-810 discontinued after failing primary endpoint in lumbosacral radicular pain Phase 2a.","Initiated Phase 1 PK trial for ETX-155; results expected Q4 2022; Phase 2a MDD planned Q1 2023.","Cash runway now expected to fund operations into 2025 due to ETX-810 discontinuation.","R&D expenses $8.8M (up from $5.8M YoY); G&A $4.9M (up from $2.9M YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-017192","json":"https://secwatch.observer/filing/0000950170-22-017192.json","markdown":"https://secwatch.observer/filing/0000950170-22-017192.md","text":"https://secwatch.observer/filing/0000950170-22-017192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000095017022017192/0000950170-22-017192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000095017022017192/elym-20220815.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:58:19.543588+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}